Full Text View
Tabular View
No Study Results Posted
Related Studies
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
This study is ongoing, but not recruiting participants.
Study NCT00412061   Information provided by Novartis
First Received: December 13, 2006   Last Updated: November 18, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Carcinoid Tumor
Malignant Carcinoid Syndrome
Additional conditions recognized in this trial
Serotonin Syndrome
Syndrome
More general conditions related to this trial
Adenocarcinoma
Carcinoma
Disease
Disorders of Environmental Origin
Drug Toxicity
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Pathologic Processes
Poisoning
Interventions listed in this trial
Octrotide with Everolimus
Octrotide depot with placebo
Additional drug interventions recognized in this trial
Everolimus
Octreotide
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Gastrointestinal Agents
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Novartis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services